Trial Profile
Pilot study: inflammation and coronary artery disease. Role of AT1 [angiotensin II type I] receptor antagonism
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary)
- Indications Coronary artery disease; Essential hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 28 Mar 2007 New trial record.